Who
David Krempa
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Eton Pharmaceuticals.
In numbers
- Trades disclosed
- 62
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $10.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Feb 2024
- Last trade
- 6 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 6 Oct 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $229K4,166 at $55.07 | filing |
| 2 Oct 2026filed 6 Oct 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —10,522 | filing |
| 2 Oct 2026filed 6 Oct 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,522 at $0.00 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $183K25,000 at $7.31 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.6M25,000 at $65.07 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $183K25,000 at $7.31 | filing |
| 24 Aug 2026filed 24 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.6M25,000 at $65.07 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —128,985 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —128,985 at $0.00 | filing |
| 12 Jul 2026filed 13 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —10,000 | filing |
| 12 Jul 2026filed 13 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Jul 2026filed 13 Jul 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Jul 2026filed 13 Jul 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —10,000 | filing |
| 26 Jun 2026filed 30 Jun 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $619K19,679 at $31.47 | filing |
| 27 May 2026filed 27 May 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,476 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —7,203 at $0.00 | filing |
News
Contrasting Eton Pharmaceuticals (NASDAQ:ETON) and Biofrontera (NASDAQ:BFRI)ETON · themarketsdaily.com · 24 Oct 2026Eton (NASDAQ: ETON) secures LIBERVANT license with milestones up to $47.5 millionETON · themarketsdaily.com · 14 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmETON · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name David Krempa; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.